Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C11H16N2O5.ClH |
| Molecular Weight | 292.716 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@@]12CC[C@@](NC(=O)[C@H](C)N)(C(O)=O)[C@]1([H])[C@H]2C(O)=O
InChI
InChIKey=TWZDLCLCMKMJPE-OAOSNHGPSA-N
InChI=1S/C11H16N2O5.ClH/c1-4(12)8(14)13-11(10(17)18)3-2-5-6(7(5)11)9(15)16;/h4-7H,2-3,12H2,1H3,(H,13,14)(H,15,16)(H,17,18);1H/t4-,5-,6-,7-,11-;/m0./s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/12789623https://www.ncbi.nlm.nih.gov/pubmed/16223873 | https://www.ncbi.nlm.nih.gov/pubmed/15821951Curator's Comment: description was created based on several sources, including:
http://adisinsight.springer.com/drugs/800008428
https://en.wikipedia.org/wiki/Eglumegad
https://www.ncbi.nlm.nih.gov/pubmed/17712352
https://www.ncbi.nlm.nih.gov/pubmed/17204749
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12789623https://www.ncbi.nlm.nih.gov/pubmed/16223873 | https://www.ncbi.nlm.nih.gov/pubmed/15821951
Curator's Comment: description was created based on several sources, including:
http://adisinsight.springer.com/drugs/800008428
https://en.wikipedia.org/wiki/Eglumegad
https://www.ncbi.nlm.nih.gov/pubmed/17712352
https://www.ncbi.nlm.nih.gov/pubmed/17204749
Talaglumetad (also known as LY-544344) is a bicyclohexane derivative patented by Eli Lilly and Company as modulators of metabotropic glutamate receptor. Talaglumetad acts as a prodrug of Eglumegad, a selective agonist of metabotropic glutamate receptors (mGluR2/3) and metabolized to release active compound by both human jejunal homogenates and rat liver homogenates. In experiments on mice, Talaglumetad was found to be as effective as diazepam for treating anxiety symptoms in several standard tests, but without producing any of the negative side effects of diazepam such as sedation and memory impairment.
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
200 mg 1 times / day multiple, oral (unknown) Studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy n = 18 Health Status: unhealthy Condition: panic disorder Sex: M+F Food Status: UNKNOWN Population Size: 18 Sources: |
Disc. AE: headache, Nausea... AEs leading to discontinuation/dose reduction: headache (1 pt) Sources: Nausea (1 pt) allergic reaction (2 patients) Dizziness (1 pt) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Dizziness | 1 pt Disc. AE |
200 mg 1 times / day multiple, oral (unknown) Studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy n = 18 Health Status: unhealthy Condition: panic disorder Sex: M+F Food Status: UNKNOWN Population Size: 18 Sources: |
| Nausea | 1 pt Disc. AE |
200 mg 1 times / day multiple, oral (unknown) Studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy n = 18 Health Status: unhealthy Condition: panic disorder Sex: M+F Food Status: UNKNOWN Population Size: 18 Sources: |
| headache | 1 pt Disc. AE |
200 mg 1 times / day multiple, oral (unknown) Studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy n = 18 Health Status: unhealthy Condition: panic disorder Sex: M+F Food Status: UNKNOWN Population Size: 18 Sources: |
| allergic reaction | 2 patients Disc. AE |
200 mg 1 times / day multiple, oral (unknown) Studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy n = 18 Health Status: unhealthy Condition: panic disorder Sex: M+F Food Status: UNKNOWN Population Size: 18 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| A novel orally active group 2 metabotropic glutamate receptor agonist: LY354740. | 1997 Apr 14 |
|
| LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors. | 1997 Jan |
|
| Characterization of [3H]-(2S,2'R,3'R)-2-(2',3'-dicarboxy-cyclopropyl)glycine ([3H]-DCG IV) binding to metabotropic mGlu2 receptor-transfected cell membranes. | 1998 Feb |
|
| LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats. | 1998 Oct |
|
| Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. | 1999 Dec |
|
| The role of metabotropic glutamate receptor (mGluR) ligands in parkinsonian muscle rigidity. | 2000 |
|
| Characterization of [(3)H]-LY354740 binding to rat mGlu2 and mGlu3 receptors expressed in CHO cells using semliki forest virus vectors. | 2000 Jul 24 |
|
| The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration. | 2001 Oct |
|
| The role of striatal metabotropic glutamate receptors in Parkinson's disease. | 2002 |
|
| Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors. | 2002 Sep |
|
| LY-354740 (Eli Lilly). | 2003 Jan |
|
| Gateways to clinical trials. | 2005 Jun |
|
| 5-Hydroxytryptamine2A (5-HT2A) receptor regulation in rat prefrontal cortex: interaction of a phenethylamine hallucinogen and the metabotropic glutamate2/3 receptor agonist LY354740. | 2006 Aug 7 |
|
| The mGlu2/3 receptor agonist LY354740 suppresses immobilization stress-induced increase in rat prefrontal cortical BDNF mRNA expression. | 2006 May 8 |
|
| Transepithelial transport of the group II metabotropic glutamate 2/3 receptor agonist (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740) and its prodrug (1S,2S,5R,6S)-2-[(2'S)-(2'-amino)propionyl]aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY544344). | 2009 Jan |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: 8 or 16 mg twice per day (LY544344). LY544344 is a LY354740 prodrug that increases LY354740 bioavailability.
https://www.ncbi.nlm.nih.gov/pubmed/17712352
100 or 200 mg (LY354740)
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C28197
Created by
admin on Fri Dec 15 17:20:50 GMT 2023 , Edited by admin on Fri Dec 15 17:20:50 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID40963180
Created by
admin on Fri Dec 15 17:20:50 GMT 2023 , Edited by admin on Fri Dec 15 17:20:50 GMT 2023
|
PRIMARY | |||
|
300000044511
Created by
admin on Fri Dec 15 17:20:50 GMT 2023 , Edited by admin on Fri Dec 15 17:20:50 GMT 2023
|
PRIMARY | |||
|
PP-78
Created by
admin on Fri Dec 15 17:20:50 GMT 2023 , Edited by admin on Fri Dec 15 17:20:50 GMT 2023
|
PRIMARY | |||
|
CHEMBL1189257
Created by
admin on Fri Dec 15 17:20:50 GMT 2023 , Edited by admin on Fri Dec 15 17:20:50 GMT 2023
|
PRIMARY | |||
|
C81620
Created by
admin on Fri Dec 15 17:20:50 GMT 2023 , Edited by admin on Fri Dec 15 17:20:50 GMT 2023
|
PRIMARY | |||
|
441765-97-5
Created by
admin on Fri Dec 15 17:20:50 GMT 2023 , Edited by admin on Fri Dec 15 17:20:50 GMT 2023
|
PRIMARY | |||
|
9857255
Created by
admin on Fri Dec 15 17:20:50 GMT 2023 , Edited by admin on Fri Dec 15 17:20:50 GMT 2023
|
PRIMARY | |||
|
X30300EU7I
Created by
admin on Fri Dec 15 17:20:50 GMT 2023 , Edited by admin on Fri Dec 15 17:20:50 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
